• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发性雷诺现象和系统性硬化症患者的微量营养素抗氧化状态。

Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis.

作者信息

Herrick A L, Rieley F, Schofield D, Hollis S, Braganza J M, Jayson M I

机构信息

University of Manchester Rheumatic Diseases Centre, Hope Hospital, Salford, UK.

出版信息

J Rheumatol. 1994 Aug;21(8):1477-83.

PMID:7983650
Abstract

OBJECTIVE

To investigate the possibility that micronutrient antioxidant status is an important factor in determining the severity of Raynaud's phenomenon (RP) and in differentiating between patients with primary Raynaud's phenomenon (PRP) and those in whom Raynaud's is secondary to systemic sclerosis (SSc).

METHODS

Four micronutrient antioxidants (selenium, vitamin E, beta-carotene and ascorbic acid) and 2 "markers" of free radical associated activity were assayed in peripheral blood from 10 patients with PRP, 9 with limited cutaneous SSc (ISSc), 9 with diffuse SSc (dSSc) and 15 healthy control subjects.

RESULTS

Plasma ascorbic acid was reduced in all 3 groups of patients: median level 10.6 mg/l in controls, 4.8 mg/l in PRP (p < 0.01), 2.5 mg/l in ISSc (p < 0.01) and 6.8 mg/l in dSSc (p < 0.05). A reduction in serum selenium was especially found in dSSc (median 75 micrograms/l compared to 100 micrograms/l in controls, p < 0.05). In keeping with these deficiencies, the serum concentration of 9, 11, linoleic acid was elevated in RP patients: median values for the molar ratio of the isomer to the parent fatty acid were 1.91% in controls, 3.70% in ISSc (p < 0.05) and 3.85% in dSSc (p < 0.01). Smoking patients showed lower levels of ascorbic acid and higher levels of the linoleic isomer than nonsmokers.

CONCLUSION

Deficiencies of ascorbic acid and selenium may predispose towards irreversible tissue injury in RP patients and cigarette smoke may be an independent risk factor. Micronutrient antioxidant supplements may be of therapeutic value.

摘要

目的

探讨微量营养素抗氧化状态是否是决定雷诺现象(RP)严重程度以及区分原发性雷诺现象(PRP)患者和继发于系统性硬化症(SSc)的雷诺现象患者的重要因素。

方法

对10例PRP患者、9例局限性皮肤型SSc(lSSc)患者、9例弥漫性皮肤型SSc(dSSc)患者和15名健康对照者的外周血进行了4种微量营养素抗氧化剂(硒、维生素E、β-胡萝卜素和抗坏血酸)以及2种自由基相关活性“标志物”的检测。

结果

所有3组患者的血浆抗坏血酸均降低:对照组中位数水平为10.6mg/L,PRP组为4.8mg/L(p<0.01),lSSc组为2.5mg/L(p<0.01),dSSc组为6.8mg/L(p<0.05)。尤其在dSSc组发现血清硒降低(中位数75μg/L,对照组为100μg/L,p<0.05)。与这些缺乏情况一致,RP患者血清9,11-亚油酸浓度升高:异构体与母体脂肪酸摩尔比的中位数在对照组为1.91%,lSSc组为3.70%(p<0.05),dSSc组为3.85%(p<0.01)。吸烟患者的抗坏血酸水平较低,亚油酸异构体水平高于非吸烟者。

结论

抗坏血酸和硒缺乏可能使RP患者易发生不可逆组织损伤,吸烟可能是一个独立危险因素。微量营养素抗氧化剂补充剂可能具有治疗价值。

相似文献

1
Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis.原发性雷诺现象和系统性硬化症患者的微量营养素抗氧化状态。
J Rheumatol. 1994 Aug;21(8):1477-83.
2
Dietary intake of micronutrient antioxidants in relation to blood levels in patients with systemic sclerosis.系统性硬化症患者的微量营养素抗氧化剂膳食摄入量与血液水平的关系
J Rheumatol. 1996 Apr;23(4):650-3.
3
Serum concentrations of beta-carotene, vitamins C and E, zinc and selenium are influenced by sex, age, diet, smoking status, alcohol consumption and corpulence in a general French adult population.在法国普通成年人群中,血清β-胡萝卜素、维生素C和E、锌和硒的浓度受性别、年龄、饮食、吸烟状况、饮酒量和肥胖程度的影响。
Eur J Clin Nutr. 2005 Oct;59(10):1181-90. doi: 10.1038/sj.ejcn.1602230.
4
Homocysteine concentration in primary and systemic sclerosis associated Raynaud's phenomenon.原发性和系统性硬化症相关雷诺现象中的同型半胱氨酸浓度。
J Rheumatol. 2000 Nov;27(11):2621-3.
5
Increased circulating platelet-leucocyte complexes in patients with primary Raynaud's phenomenon and Raynaud's phenomenon secondary to systemic sclerosis: a comparative study.原发性雷诺现象及系统性硬化症继发雷诺现象患者循环血小板 - 白细胞复合物增加:一项对比研究。
Blood Coagul Fibrinolysis. 2007 Jun;18(4):297-302. doi: 10.1097/MBC.0b013e328010bd05.
6
Elevated plasma adrenomedullin and vascular manifestations in patients with systemic sclerosis.系统性硬化症患者血浆肾上腺髓质素升高与血管表现
J Rheumatol. 2007 Nov;34(11):2224-9. Epub 2007 Oct 15.
7
[Platelet function study in primary Raynaud's phenomenon and Raynaud's phenomenon associated with scleroderma].原发性雷诺现象及与硬皮病相关的雷诺现象中的血小板功能研究
Med Clin (Barc). 1990 Dec 8;95(20):761-3.
8
Increased urinary F2-isoprostanes in systemic sclerosis, but not in primary Raynaud's phenomenon: effect of cold exposure.系统性硬化症患者尿中F2-异前列腺素水平升高,而原发性雷诺现象患者则不然:寒冷暴露的影响。
Arthritis Rheum. 2002 May;46(5):1319-23. doi: 10.1002/art.10261.
9
Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls.系统性硬化症患者、原发性雷诺现象患者及正常对照者的血清基质金属蛋白酶组织抑制因子-1、基质金属蛋白酶组织抑制因子-2和基质金属蛋白酶-1 。
Ann Rheum Dis. 2001 Sep;60(9):846-51.
10
Raynaud's phenomenon and plasma endothelin: correlations with capillaroscopic patterns in systemic sclerosis.雷诺现象与血浆内皮素:与系统性硬化症毛细血管镜检查模式的相关性
J Rheumatol. 2009 Jun;36(6):1235-9. doi: 10.3899/jrheum.081030. Epub 2009 Apr 15.

引用本文的文献

1
Forearm porphyrin levels evaluated by digital imaging system are increased in patients with systemic sclerosis compared with patients in pre-clinical stage.与临床前期患者相比,通过数字成像系统评估的系统性硬化症患者的前臂卟啉水平升高。
Intractable Rare Dis Res. 2022 Feb;11(1):1-6. doi: 10.5582/irdr.2021.01157.
2
Raynaud's Phenomenon: Reviewing the Pathophysiology and Management Strategies.雷诺现象:病理生理学与管理策略综述
Cureus. 2022 Jan 28;14(1):e21681. doi: 10.7759/cureus.21681. eCollection 2022 Jan.
3
Serum Concentrations of Trace Elements/Minerals in Patients with Diffuse Systemic Sclerosis.
弥漫性系统性硬皮病患者的微量元素/矿物质血清浓度。
Biol Trace Elem Res. 2021 Jul;199(7):2440-2443. doi: 10.1007/s12011-020-02368-5. Epub 2020 Sep 3.
4
Oxidative stress in the pathogenesis of systemic scleroderma: An overview.系统性硬皮病发病机制中的氧化应激:概述。
J Cell Mol Med. 2018 Jul;22(7):3308-3314. doi: 10.1111/jcmm.13630. Epub 2018 Apr 17.
5
Genistein protects dermal fibrosis in bleomycin-induced experimental scleroderma.金雀异黄素可保护博来霉素诱导的实验性硬皮病中的皮肤纤维化。
Eur J Rheumatol. 2015 Sep;2(3):99-102. doi: 10.5152/eurjrheum.2015.0110. Epub 2015 May 20.
6
Lipoic acid plays a role in scleroderma: insights obtained from scleroderma dermal fibroblasts.硫辛酸在硬皮病中的作用:来自硬皮病皮肤成纤维细胞的见解。
Arthritis Res Ther. 2014;16(5):411. doi: 10.1186/s13075-014-0411-6.
7
Redox signaling as a therapeutic target to inhibit myofibroblast activation in degenerative fibrotic disease.氧化还原信号传导作为抑制退行性纤维化疾病中肌成纤维细胞激活的治疗靶点。
Biomed Res Int. 2014;2014:131737. doi: 10.1155/2014/131737. Epub 2014 Feb 20.
8
Epigenetic repression of bone morphogenetic protein receptor II expression in scleroderma.硬皮病中骨形态发生蛋白受体 II 表达的表观遗传抑制。
J Cell Mol Med. 2013 Oct;17(10):1291-9. doi: 10.1111/jcmm.12105. Epub 2013 Jul 16.
9
Serum antioxidant status in patients with systemic sclerosis.系统性硬化症患者的血清抗氧化状态
Indian J Dermatol. 2013 May;58(3):239. doi: 10.4103/0019-5154.110840.
10
Scleroderma therapy: clinical overview of current trends and future perspective.硬皮病治疗:当前趋势的临床概述及未来展望。
Rheumatol Int. 2013 Jan;33(1):1-18. doi: 10.1007/s00296-012-2486-1. Epub 2012 Aug 3.